MCID: AVN001
MIFTS: 56

Avian Influenza

Categories: Infectious diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Avian Influenza

MalaCards integrated aliases for Avian Influenza:

Name: Avian Influenza 12 59 3 15 17
Influenza in Birds 44 72
Bird Flu 12 43
Avian Flu 12

Characteristics:

Orphanet epidemiological data:

59
avian influenza
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4492
MeSH 44 D005585
SNOMED-CT 68 55604004
ICD10 33 J09.X
ICD10 via Orphanet 34 J09
Orphanet 59 ORPHA454836
UMLS 72 C0016627

Summaries for Avian Influenza

MedlinePlus : 43 Birds, just like people, get the flu. Bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. Usually bird flu viruses only infect other birds. It is rare for people to get infected with bird flu viruses, but it can happen. Two types, H5N1 and H7N9, have infected some people during outbreaks in Asia, Africa, the Pacific, the Middle East, and parts of Europe. There have also been some rare cases of other types of bird flu affecting people in the United States. Most of the people who get bird flu have had close contact with infected birds or with surfaces that have been contaminated by the birds' saliva, mucous, or droppings. It is also possible to get it by breathing in droplets or dust that contain the virus. Rarely, the virus has spread from one person to another. It may also be possible to catch bird flu by eating poultry or eggs that are not well cooked. Bird flu illness in people can range from mild to severe. Often, the symptoms are similar to the seasonal flu, such as Fever Cough Sore throat Runny or stuffy nose Muscle or body aches Fatigue Headaches Eye redness (or conjunctivitis) Difficulty breathing In some cases, bird flu can cause serious complications and death. As with seasonal flu, some people are at higher risk for serious illness. They include pregnant women, people with weakened immune systems, and adults 65 and older. Treatment with antiviral medicines may make the illness less severe. They may also help prevent the flu in people who were exposed to it. There is currently no vaccine available to the public. The government does have a supply of a vaccine for one type of H5N1 bird flu virus and could distribute it if there was an outbreak that spread easily from person to person. Centers for Disease Control and Prevention

MalaCards based summary : Avian Influenza, also known as influenza in birds, is related to severe acute respiratory syndrome and swine influenza, and has symptoms including fever, pruritus and snoring. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Oseltamivir and Probenecid have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

CDC : 3 Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. The links below offer more information about avian influenza.

Wikipedia : 75 Avian influenza-known informally as avian flu or bird flu is a variety of influenza caused by viruses... more...

Related Diseases for Avian Influenza

Diseases related to Avian Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 severe acute respiratory syndrome 31.5 TNF CXCL8 CXCL10
2 swine influenza 31.2 TNF NEU1 HAS1
3 bacterial infectious disease 31.0 TNF IL6 CXCL8
4 peritonitis 30.9 TNF IL6 CXCL8
5 acute respiratory distress syndrome 30.9 TNF SFTPD IL6 CXCL8
6 bronchiolitis 30.7 TNF IL6 CXCL8
7 toxic shock syndrome 30.7 TNF IL6 CXCL8
8 respiratory failure 30.7 TNF SFTPD CXCL8
9 chikungunya 30.6 TNF IL6 DDX58
10 gastroenteritis 30.6 TNF IL6 CXCL8
11 adult respiratory distress syndrome 30.5 TNF IL6 CXCL8
12 upper respiratory tract disease 30.5 TNF IL6 CXCL8
13 japanese encephalitis 30.4 TNF DDX58 CXCL10
14 bacterial pneumonia 30.4 SFTPD IL6 CXCL8
15 streptococcal toxic-shock syndrome 30.3 TNF IL6 CXCL8
16 hemorrhagic fever with renal syndrome 30.3 TNF IL6 CXCL8
17 leptospirosis 30.3 TNF IL6 CXCL8
18 pneumonia 30.3 TNF SFTPD IL6 CXCL8
19 bronchiolitis obliterans 30.3 TNF IL6 CXCL8
20 chlamydia 30.2 TNF IL6 CXCL8
21 intestinal disease 30.1 TNF IL6 CXCL8
22 measles 30.0 STAT2 IL6 DDX58
23 laryngitis 29.9 TNF IL6
24 viral infectious disease 29.7 TNF IRF7 IL6 DDX58 CXCL8 CXCL10
25 glossitis 29.6 TNF IL6
26 lung disease 29.6 TNF SFTPD IL6 CXCL8 CXCL10
27 human immunodeficiency virus type 1 28.9 TNF IL6 CXCL10 CCR1
28 influenza 11.5
29 newcastle disease 11.0
30 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.8
31 conjunctivitis 10.7
32 bronchitis 10.6
33 plague 10.6
34 scorpion envenomation 10.6 TNF IL6
35 lymphopenia 10.6
36 exudative glomerulonephritis 10.6 TNF CXCL8
37 recurrent corneal erosion 10.6 IL6 CXCL8
38 bagassosis 10.5 IL6 CXCL8
39 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 TNF IL6
40 autoimmune myocarditis 10.5 TNF IL6
41 acute transverse myelitis 10.5 IL6 CXCL8
42 vaccinia 10.5
43 viral pneumonia 10.5
44 cytokine deficiency 10.5
45 tungiasis 10.5 TNF CXCL8
46 encephalitis 10.4
47 viral meningitis 10.4 IL6 CXCL8 CXCL10
48 acute pyelonephritis 10.4 IL6 CXCL8 CXCL10
49 cardiogenic shock 10.4 TNF IL6
50 crimean-congo hemorrhagic fever 10.4 TNF IL6 CXCL10

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to Avian Influenza

Symptoms & Phenotypes for Avian Influenza

UMLS symptoms related to Avian Influenza:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Avian Influenza:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 CCR1 CRK CXCL10 FURIN IL6 NEU1
2 hematopoietic system MP:0005397 10 CCR1 CXCL10 DDX58 FURIN IL6 IRF7
3 digestive/alimentary MP:0005381 9.92 CCR1 CRK DDX58 FURIN IL6 PCSK5
4 immune system MP:0005387 9.9 CCR1 CXCL10 DDX58 FURIN IL6 IRF7
5 mortality/aging MP:0010768 9.77 CCR1 CRK CXCL10 DDX58 FURIN IL6
6 respiratory system MP:0005388 9.23 CCR1 CRK IL6 NEU1 PCSK5 PCSK6

Drugs & Therapeutics for Avian Influenza

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Probenecid Approved, Investigational Phase 4 57-66-9 4911
3 Antiviral Agents Phase 4
4 Anti-Infective Agents Phase 4
5 Renal Agents Phase 4
6 Antirheumatic Agents Phase 4
7
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
8
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
9 Hemagglutinins Phase 2, Phase 3
10 Agglutinins Phase 2, Phase 3
11 Cathartics Phase 3
12 Immunosuppressive Agents Phase 3
13 Laxatives Phase 3
14
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
15
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
16
Aluminum sulfate Approved Phase 2 10043-01-3
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
18 Tocotrienol Investigational Phase 2 6829-55-6
19 MF59 oil emulsion Phase 2
20 Tocotrienols Phase 2
21 Tocopherols Phase 2
22 Pharmaceutical Solutions Phase 1, Phase 2
23 Adjuvants, Immunologic Phase 2
24 Gastrointestinal Agents Phase 2
25 Antacids Phase 2
26 Anti-Ulcer Agents Phase 2
27 Antibodies Phase 2
28 Immunologic Factors Phase 1, Phase 2
29 gamma-Globulins Phase 2
30 Vaccines Phase 1, Phase 2
31 Immunoglobulins Phase 2
32 Immunoglobulins, Intravenous Phase 2
33 Rho(D) Immune Globulin Phase 2
34 interferons Phase 1, Phase 2
35 Interferon Inducers Phase 1, Phase 2
36 Poly I-C Phase 1, Phase 2
37 poly(I).poly(c12,U) Phase 1, Phase 2
38
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
39
Peramivir Approved, Investigational Phase 1 330600-85-6, 229614-55-5 151164
40
Inulin Approved, Investigational, Nutraceutical Phase 1 9005-80-5 24763
41 ISCOMs Phase 1

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) Completed NCT00304434 Phase 4 Oseltamivir;Probenecid
2 Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response Recruiting NCT03701061 Phase 4
3 A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Completed NCT02839330 Phase 3
4 A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions Completed NCT02107807 Phase 3
5 A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC Completed NCT02612909 Phase 2, Phase 3
6 Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Completed NCT01310413 Phase 3
7 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Completed NCT00434733 Phase 3
8 A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years Completed NCT01382329 Phase 2, Phase 3
9 Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Completed NCT01788228 Phase 3
10 Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers Completed NCT01987011 Phase 3
11 Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions. Completed NCT02091908 Phase 3
12 Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. Completed NCT00328107 Phase 2, Phase 3
13 Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49 Completed NCT00539981 Phase 3
14 Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh Completed NCT00707941 Phase 3 Oseltamivir;Placebo
15 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. Withdrawn NCT01546935 Phase 2, Phase 3 Oseltamivir
16 A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses Unknown status NCT00417560 Phase 1, Phase 2
17 A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines Completed NCT00478816 Phase 2
18 A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years Completed NCT00537524 Phase 2
19 A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64 Completed NCT00695669 Phase 2
20 Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study Completed NCT02229357 Phase 2
21 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010) Completed NCT01910519 Phase 2
22 High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial Completed NCT00298233 Phase 2 Oseltamivir
23 A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects Completed NCT00481065 Phase 2
24 Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine Completed NCT01578317 Phase 1, Phase 2
25 A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects Completed NCT02436928 Phase 1, Phase 2
26 A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults Completed NCT00703053 Phase 2
27 A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine Completed NCT01195038 Phase 2
28 A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects Completed NCT00561184 Phase 2
29 A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults. Completed NCT00980447 Phase 2
30 A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™ Completed NCT02078674 Phase 1, Phase 2
31 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities Completed NCT00311649 Phase 1, Phase 2
32 A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study Completed NCT00680069 Phase 1, Phase 2
33 A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses Completed NCT02921997 Phase 2 AS03
34 A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine Completed NCT03318315 Phase 2 AS03
35 A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages Completed NCT02213354 Phase 2 MF59
36 Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years Completed NCT01416571 Phase 2
37 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects. Completed NCT01776554 Phase 2
38 A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects. Completed NCT01776541 Phase 2
39 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects. Completed NCT01766921 Phase 2
40 Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants Completed NCT00376402 Phase 2
41 Phase II Study of a Pandemic Influenza Vaccine in Children Completed NCT00370864 Phase 2
42 A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years Completed NCT01052402 Phase 1, Phase 2
43 Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children Completed NCT00884182 Phase 2
44 A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Completed NCT00914771 Phase 2
45 An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years Completed NCT00895544 Phase 1, Phase 2
46 A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age Completed NCT00771615 Phase 2
47 Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers Completed NCT01389466 Phase 1, Phase 2
48 A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age). Completed NCT00320346 Phase 2
49 A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two Surface Antigen Adjuvanted With MF59C.1 Influenza Vaccines Containing 7.5 Micrograms or 15 Micrograms of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 Micrograms of A/H5N1 Influenza Antigen, in Adults Completed NCT00382187 Phase 2
50 Randomized, Double-Blinded, Phase 2 Study to Assess Safety & Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With & Without Stored MF59® Adjuvant Completed NCT02680002 Phase 2

Search NIH Clinical Center for Avian Influenza

Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

Anatomical Context for Avian Influenza

MalaCards organs/tissues related to Avian Influenza:

41
Testes, Lung, T Cells, Eye, B Cells, Brain, Kidney

Publications for Avian Influenza

Articles related to Avian Influenza:

(show top 50) (show all 9890)
# Title Authors PMID Year
1
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts. 38 17
31266524 2019
2
Influenza A viruses in birds and humans: Prevalence, molecular characterization, zoonotic significance and risk factors' assessment in poultry farms. 38 17
30961818 2019
3
Identifying Risk Factors Of A(H7N9) Outbreak by Wavelet Analysis and Generalized Estimating Equation. 17
31013684 2019
4
Estimated Incubation Period and Serial Interval for Human-to-Human Influenza A(H7N9) Virus Transmission. 38
31264568 2019
5
Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. 38
31324565 2019
6
Emergence of waterfowl-originated gene cassettes in HPAI H7N9 viruses caused severe human infection in Fujian, China. 38
31187583 2019
7
Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay. 38
31411006 2019
8
Mobile phone-based surveillance for animal disease in rural communities: implications for detection of zoonoses spillover. 38
31401960 2019
9
Immunosuppressive potential of fowl adenovirus serotype 4. 38
30993349 2019
10
Effects of cage size on growth performance, blood biochemistry, and antibody response in layer breeder males during rearing stage. 38
30895313 2019
11
Epidemic growth rates and host movement patterns shape management performance for pathogen spillover at the wildlife-livestock interface. 38
31401952 2019
12
Chinese poultry farmers' decision-making for avian influenza prevention: a qualitative analysis. 38
31215154 2019
13
Intercontinental spread of Asian-origin H7 avian influenza viruses by captive bird trade in 1990's. 38
31054314 2019
14
ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells. 38
31217244 2019
15
Genotypic evolution and epidemiological characteristics of H9N2 influenza virus in Shandong Province, China. 38
30941436 2019
16
Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. 38
31259864 2019
17
Genetic characteristics and polymorphisms in the chicken interferon-induced transmembrane protein (IFITM3) gene. 38
31410631 2019
18
Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. 38
31370782 2019
19
Clade 2.3.2.1 H5N1 avian influenza viruses circulate at the interface of migratory and domestic birds around Qinghai Lake in China. 38
31383307 2019
20
A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir. 38
31282375 2019
21
Characterization of avian influenza H5N3 reassortants isolated from migratory waterfowl and domestic ducks in China from 2015 to 2018. 38
31402584 2019
22
Viral interference between H9N2-low pathogenic avian influenza virus and avian infectious bronchitis virus vaccine strain H120 in vivo. 38
31300117 2019
23
Comparison of nucleic acid extraction methods for next-generation sequencing of avian influenza A virus from ferret respiratory samples. 38
31004662 2019
24
First outbreak of human infection with avian influenza A(H7N9) virus in Guangxi, China, 2016 to 2017. 38
31348034 2019
25
Avian influenza A viruses H5Nx (N1, N2, N6 and N8) show different adaptations of their codon usage patterns to their hosts. 38
31029693 2019
26
Airborne transmission may have played a role in the spread of 2015 highly pathogenic avian influenza outbreaks in the United States. 38
31409807 2019
27
A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza. 38
31399519 2019
28
Comparative immune response and pathogenicity of the H9N2 avian influenza virus after administration of Immulant®, based on Echinacea and Nigella sativa, in stressed chickens. 38
31300109 2019
29
Co-infections of chickens with Avian Influenza Virus H9N2 and Moroccan Italy 02 Infectious Bronchitis Virus: effect on pathogenesis and protection conferred by different vaccination programs. 38
31412705 2019
30
Variable impact of the hemagglutinin polybasic cleavage site on virulence and pathogenesis of avian influenza H7N7 virus in chickens, turkeys and ducks. 38
31399610 2019
31
Knowledge, attitudes, and practices relevant to zoonotic disease reporting and infection prevention practices among veterinarians - Arizona, 2015. 38
31311640 2019
32
Establishment of a Simultaneous Detection Method for Ten Duck Viruses Using MALDI-TOF Mass Spectrometry. 38
31430495 2019
33
Newcastle disease virus vectors expressing consensus sequence of the H7 HA protein protect broiler chickens and turkeys against highly pathogenic H7N8 virus. 38
31320218 2019
34
Detection of highly pathogenic avian influenza A(H5N6) viruses in waterfowl in Bangladesh. 38
31176062 2019
35
Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses. 38
31424377 2019
36
Factors associated with fatality due to avian influenza A(H7N9) infection in China. 38
31418813 2019
37
Nationwide groundwater monitoring around infectious-disease-caused livestock mortality burials in Korea: Superimposed influence of animal leachate on pre-existing anthropogenic pollution. 38
31150979 2019
38
Human Seroprevalence to 11 Zoonotic Pathogens in the U.S. Arctic, Alaska. 38
30789314 2019
39
Impact of Dietary Organic Mineral Supplementation on Reproductive Performance, Egg Quality Characteristics, Lipid Oxidation, Ovarian Follicular Development, and Immune Response in Laying Hens Under High Ambient Temperature. 38
31418151 2019
40
Glycan-immobilized dual-channel field effect transistor biosensor for the rapid identification of pandemic influenza viral particles. 38
31406167 2019
41
Artificial intelligence and avian influenza: Using machine learning to enhance active surveillance for avian influenza viruses. 38
31376332 2019
42
Effective mosaic-based nanovaccines against avian influenza in poultry. 38
31300285 2019
43
The codon usage bias of avian influenza A viruses. 38
31075292 2019
44
Inventory of molecular markers affecting biological characteristics of avian influenza A viruses. 38
31428925 2019
45
Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. 38
31421167 2019
46
PB2 and hemagglutinin mutations confer a virulent phenotype on an H1N2 avian influenza virus in mice. 38
31111259 2019
47
Bayesian phylodynamics of avian influenza A virus H9N2 in Asia with time-dependent predictors of migration. 38
31386651 2019
48
Semiaquatic mammals might be intermediate hosts to spread avian influenza viruses from avian to human. 38
31406229 2019
49
Global patterns of avian influenza A(H7): virus evolution and zoonotic threats. 38
31381759 2019
50
A Single Mutation N166D in Hemagglutinin Affects Antigenicity and Pathogenesis of H9N2 Avian Influenza Virus. 38
31382442 2019

Variations for Avian Influenza

Expression for Avian Influenza

Search GEO for disease gene expression data for Avian Influenza.

Pathways for Avian Influenza

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TNF STAT2 NEU1 IRF7 IL6 DDX58
2
Show member pathways
13.21 TNF IL6 CXCL8 CXCL10 CRK CCR1
3
Show member pathways
13.02 TNF STAT2 IRF7 IL6 DDX58 CXCL8
4
Show member pathways
12.85 TNF STAT2 SFTPD IRF7 IL6 CXCL8
5
Show member pathways
12.77 STAT2 CXCL8 CXCL10 CRK CCR1
6
Show member pathways
12.58 TNF IRF7 IL6 DDX58 CXCL8 CXCL10
7
Show member pathways
12.55 TNF STAT2 IRF7 IL6 DDX58 CXCL8
8 12.41 TNF STAT2 IRF7 DDX58 CXCL10
9
Show member pathways
12.22 TNF IL6 CXCL8 CXCL10
10
Show member pathways
12.21 TNF IL6 CXCL8 CRK
11
Show member pathways
12.17 CXCL8 CXCL10 CCR1
12
Show member pathways
12.14 TNF IRF7 IL6 CXCL8
13
Show member pathways
12.12 TNF STAT2 IRF7 IL6 CXCL8
14
Show member pathways
11.94 TNF SFTPD IL6 CXCL8 CXCL10
15 11.9 TNF IL6 CCR1
16 11.89 TNF IL6 CXCL8
17 11.88 TNF IL6 CXCL10
18 11.86 TNF IL6 CXCL8 CXCL10
19 11.84 IRF7 IL6 CXCL8
20 11.82 TNF IL6 CXCL8
21 11.81 TNF IL6 CXCL8
22 11.81 TNF DDX58 CXCL8
23 11.79 STAT2 IL6 CCR1
24 11.77 TNF IL6 CXCL8
25 11.66 TNF IL6 CXCL8
26 11.63 TNF IL6 CXCL10
27 11.58 IL6 CXCL8 CRK
28
Show member pathways
11.55 TNF IL6 CXCL8
29 11.54 TNF IL6 CXCL8
30 11.47 TNF IL6 CXCL8
31 11.39 TNF IL6 CXCL8
32 11.07 TNF IL6 CXCL8 CXCL10
33
Show member pathways
10.99 STAT2 IRF7 DDX58
34 10.86 TNF IL6 CXCL8
35 10.71 TNF IL6 CXCL8 CXCL10 CCR1
36
Show member pathways
9.83 PCSK6 PCSK5 FURIN

GO Terms for Avian Influenza

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 TNF SFTPD PCSK6 PCSK5 IL6 FURIN
2 Golgi lumen GO:0005796 9.33 PCSK6 PCSK5 FURIN
3 extracellular region GO:0005576 9.28 TNF SFTPD PCSK6 PCSK5 NEU1 IL6

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 TNF IL6 CXCL8 CXCL10 CCR1
2 inflammatory response GO:0006954 9.85 TNF IL6 CXCL8 CXCL10 CCR1
3 cellular response to lipopolysaccharide GO:0071222 9.78 TNF IL6 CXCL8 CXCL10
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.77 TNF IL6 DDX58
5 chemokine-mediated signaling pathway GO:0070098 9.71 CXCL8 CXCL10 CCR1
6 positive regulation of interleukin-6 production GO:0032755 9.7 TNF IL6 DDX58
7 protein processing GO:0016485 9.67 PCSK6 PCSK5 FURIN
8 response to virus GO:0009615 9.67 TNF IRF7 DDX58 CXCL10
9 positive regulation of monocyte chemotaxis GO:0090026 9.61 CXCL10 CCR1
10 positive regulation of glial cell proliferation GO:0060252 9.61 TNF IL6
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 TNF FURIN
12 positive regulation of interferon-alpha production GO:0032727 9.58 IRF7 DDX58
13 signal peptide processing GO:0006465 9.58 PCSK5 FURIN
14 secretion by cell GO:0032940 9.57 PCSK6 FURIN
15 negative regulation of lipid storage GO:0010888 9.56 TNF IL6
16 defense response to virus GO:0051607 9.55 STAT2 IRF7 IL6 DDX58 CXCL10
17 positive regulation of neuroinflammatory response GO:0150078 9.51 TNF IL6
18 peptide hormone processing GO:0016486 9.5 PCSK6 PCSK5 FURIN
19 peptide biosynthetic process GO:0043043 9.43 PCSK5 FURIN
20 embryonic digestive tract development GO:0048566 9.43 TNF PCSK5 CXCL8
21 nerve growth factor production GO:0032902 9.4 PCSK6 FURIN
22 cytokine-mediated signaling pathway GO:0019221 9.17 TNF STAT2 IL6 CXCL8 CXCL10 CRK
23 regulation of lipoprotein lipase activity GO:0051004 9.13 PCSK6 PCSK5 FURIN

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.62 TMPRSS13 PCSK6 PCSK5 FURIN
2 cytokine activity GO:0005125 9.56 TNF IL6 CXCL8 CXCL10
3 endopeptidase activity GO:0004175 9.54 PCSK6 PCSK5 FURIN
4 protein binding GO:0005515 9.53 TUFM TNF STAT2 SFTPD PCSK6 PCSK5
5 serine-type peptidase activity GO:0008236 9.26 TMPRSS13 PCSK6 PCSK5 FURIN
6 nerve growth factor binding GO:0048406 9.16 PCSK6 FURIN

Sources for Avian Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....